FORT LEE, N.J., May 5 /PRNewswire-FirstCall/ -- Alpharma Inc. , a leading global generic pharmaceutical company, today announced that it has been notified by United States Food and Drug Administration that its pending application for Kadian(R) 200mg capsule has received approvable status. Kadian(R) is Alpharma's branded sustained release morphine sulfate product and is currently marketed in 20mg, 30mg, 50mg, 60mg and 100mg dosages. The company plans to launch the new dosage form following final FDA approval.
"We are extremely pleased to receive approvable status on this important new higher dosage of Kadian(R) which will help meet the needs of some the most severe sufferers of chronic pain," commented Ronald Warner, PhD, President of Alpharma's Branded Products business. "Kadian(R) already has a significant advantage over competitive products as a result of the dosing flexibility it offers physicians and their patients and is the only brand in its category that can be dosed either once or twice daily. This added dosage form, which will be marketed by our recently expanded sales force, will help physicians individualize their patients treatments by offering more choices in managing their pain."
Alpharma press releases are also available at our website: http://www.alpharma.com/.
Alpharma Inc. is a global generic pharmaceutical company with leadership positions in products for humans and animals. Uniquely positioned to expand internationally, Alpharma is presently active in more than 60 countries. Alpharma is a leading manufacturer of generic pharmaceutical products in the U.S., offering solid, liquid and topical pharmaceuticals. It is also one of the largest suppliers of generic solid dose pharmaceuticals in Europe, with a growing presence in Southeast Asia. Alpharma is among the worlds leading producers of several important pharmaceutical-grade bulk antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry, swine and cattle.
CONTACT: Kathleen Makrakis, VP, Investor Relations of Alpharma Inc.,+1-201-228-5085, email@example.com